Brixton Biosciences

What Brixton Biosciences does

Brixton Biosciences is a clinical-stage life sciences company founded in 2018 and headquartered in Cambridge, Massachusetts, developing novel non-opioid therapies for chronic and acute pain. The company is a spin-out from Massachusetts General Brigham, co-founded by R. Rox Anderson and Lilit Garibyan of Harvard Medical School/MGH, and is led by CEO Sameer Sabir. Its lead product, ReneuRx™ (formerly Neural Ice™ and originally Coolio), is a nerve-selective injectable therapy that uses a cryoneurolysis-based mechanism to temporarily desensitize targeted nerves and provide drug-free, opioid- and steroid-free pain relief lasting up to six months from a single treatment in animal models. The therapy received FDA Breakthrough Device Designation in October 2023, recognizing its potential to address unmet needs in pain management and supporting accelerated regulatory review and potential Medicare transitional pass-through payment eligibility.

The company is currently conducting multiple clinical trials across 10+ US sites — including the RENEU study for lateral hip pain, the NICE trial for knee osteoarthritis, and a thumb basal joint (CMC) arthritis study — through academic medical centers (Mass General Brigham, UT Southwestern, Emory) and orthopedic practices (Rothman Orthopedics, All-American Orthopedic). Brixton is pre-revenue, as ReneuRx remains investigational and is not yet approved or cleared for marketing by the FDA. It has raised approximately $35M in a May 2024 Series B led by Schooner Capital plus a $2M NIH HEAL Initiative grant (October 2024) to advance clinical development. The planned commercial go-to-market targets orthopedic surgeons and pain management specialists in hospital and outpatient settings, with key leadership including CMO Dr. Michael Fishman and a Scientific Advisory Board co-chaired by prominent orthopedic surgeons Dr. William J. Hozack and Dr. Brian J. Cole.

Name

Brixton Biosciences

Legal name

Brixton Biosciences, Inc.

Website

https://brixtonbio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Brixton Biosciences is a clinical-stage life sciences company developing ReneuRx, a nerve-selective, drug-free injectable therapy for chronic and acute orthopedic pain, currently conducting clinical trials toward FDA approval.

Ownership category

akta.pro rank

Product category

Pain Management Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)

Keywords

• Non-opioid pain management
• Cryoneurolysis therapy
• Nerve-selective injectables
• Chronic pain therapeutics
• Investigational medical devices

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Investigational Therapy (Pre-Revenue): Brixton Biosciences is a clinical-stage company developing a novel injectable nerve block therapy. Its product is investigational and has not been approved or cleared for marketing by the FDA. No commercial revenue is currently being generated. Upon FDA approval, the company intends to commercialize Reneurx™ through orthopedic and pain management providers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Brixton Biosciences develops Reneurx™ (formerly Neural Ice™), a nerve-selective, drug-free injectable therapy based on cryoneurolysis that targets nerves directly to provide long-lasting pain relief of up to 6 months from a single treatment. The therapy is opioid- and steroid-free, designed as a non-addictive alternative for chronic and acute orthopedic pain management (knee/hip osteoarthritis, thumb CMC joint pain, post-operative pain, headache disorders). The product is investigational and has not been approved or cleared by the FDA; it is currently administered within clinical trials at enrolled US study sites.

Product overview

Brixton Biosciences offers a single unified product: ReneuRx™ Therapy (formerly Neural Ice™). This is a nerve-selective, drug-free injectable therapy designed to provide targeted, long-lasting pain relief for up to 6 months. The therapy targets orthopedic pain conditions including knee osteoarthritis, lateral hip pain, thumb (CMC) joint pain, and headache disorders. The company is a clinical-stage life sciences company with its technology originally developed at Massachusetts General Brigham.

Differentiator

Problem solved

Functional benefit

Brands

• Neural Ice: A nerve-selective therapy formerly known as Coolio. An injectable, drug-free pain management technology designed to provide long-lasting relief from chronic and post-operative pain. Animal models demonstrate pain relief lasting 3 months or more.
• Reneurx

Products and services

• Reneurx™ Therapy (formerly Neural Ice™) A nerve-selective, opioid- and steroid-free injectable therapy designed to provide long-lasting pain relief (up to 6 months from a single treatment) for patients with chronic and acute orthopedic pain conditions including knee osteoarthritis, lateral hip pain, thumb CMC joint pain, post-operative pain, and headache disorders. It is intended to be administered by orthopedic surgeons and pain management specialists; the product is investigational and not yet FDA-approved for marketing.

Quantifiable outcome

• Pain relief lasting 3–6 months from a single treatment (demonstrated in animal models and early clinical data)
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Massachusetts General Brigham (Spin-out Origin)coreStrategic or Co-development Partner · 14 May 2024Brixton Biosciences is a spin-out from Massachusetts General Brigham. The company's technology originated from research conducted at MGH/Harvard Medical School, with founders R. Rox Anderson and Lilit Garibyan being MGH faculty. The spin-out relationship provides ongoing institutional access to research expertise and clinical infrastructure.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Pacira BioSciences: Pacira markets the iovera system, a cryoneurolysis device for non-opioid peripheral nerve pain relief, making it the closest direct competitor to Brixton's Reneurx cryoneurolysis platform in both mechanism and target indications.
• Avanos Medical: Avanos offers COOLIEF cooled radiofrequency ablation and other interventional pain management products, directly competing for the same orthopedic pain specialists and ambulatory sites targeted by Reneurx.
• Centrexion Therapeutics: Centrexion is a clinical-stage pain therapeutics company developing non-opioid treatments (including intra-articular therapies for knee OA), competing head-to-head for similar patient populations and physician prescribers.
• Scilex Holding: Scilex commercializes non-opioid pain therapies (e.g., ZTlido, SP-103) for musculoskeletal pain, overlapping with Reneurx's value proposition of opioid-sparing, long-acting interventional pain control.

Emerging players

• Sollis Therapeutics: Sollis is a clinical-stage interventional pain company developing non-opioid therapies for radicular and orthopedic pain, with overlapping clinical-development risk profile and prescriber focus.
• Axonics: Axonics develops neuromodulation devices for chronic pain and incontinence, representing an alternative interventional pain modality competing for the same payer budget and specialist referrals.
• Hinge Health: Hinge Health is a digital MSK pain management platform that increasingly competes for conservative-care patient share before they progress to interventional options like Reneurx.

Broad incumbents

• Medtronic: Medtronic operates a broad interventional pain portfolio including nerve ablation, spinal cord stimulation, and drug delivery systems, competing for the same orthopedic surgeon and pain specialist mindshare as Brixton.
• Abbott: Abbott's radiofrequency ablation and neuromodulation devices for chronic pain overlap with Reneurx's interventional pain positioning, with deeper commercial scale and reimbursement infrastructure.
• Stryker: Stryker's orthopedic surgical and joint replacement portfolio puts it adjacent to Reneurx's orthopedic pain indication set, with established arthroplasty surgeon relationships and ambulatory surgery center channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/brixtonbiosciences

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brixton Biosciences